Vishal Mega Mart promoter entity likely to sell 6.5% stake via block deal: Report
Vishal Mega Mart’s promoter, Samayat Services LLP, is set to sell a 6.5% stake through a block deal at Rs 115 per share, a 10% discount to the current market price. This move comes as the company reported a 19% rise in net profit for the December quarter.
25 stocks that survived AI crash reveal what themes could work within Indian IT space
Indian IT stocks experienced a significant downturn due to AI concerns, with the Nifty IT index falling 21% in February. However, 25 select stocks defied the slump, showing positive returns by focusing on AI infrastructure, integration, and specialized engineering, indicating potential future growth themes for the sector.
Noel Tata’s tough ask on IPO stalled vote on Chairman tenure
An early agenda item for Tata Sons Pvt.’s six board directors when they convened at 11:30 a.m. on Tuesday at Bombay House the group’s storied headquarters was expected to be straightforward: approving a third term for Natarajan Chandrasekaran as chairman.
PSU banks better placed on loan-deposit metrics; microfinance cycle nearing normalisation, says Yuvraj Choudhary
Public sector banks are showing resilience in their loan-to-deposit ratios, with a significant gap compared to private peers. Despite concerns, PSU banks are leading credit growth and demonstrating improved asset quality and return on equity, suggesting a positive near-term outlook.
Selloff in IT may offer trading bounce; metals and pharma hold long-term promise: Neeraj Dewan
Market expert Neeraj Dewan sees short-term trading bounces in IT due to overselling, but cautions on long-term AI disruption. Solar stocks might offer medium-term opportunities after sharp falls. Metals are buy-on-dips, while pharma’s GLP-1 segment faces competitive uncertainty despite structural positivity. Defence remains a long-term investment, with rerating pauses expected.
Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, Biocon
Biocon CEO Siddharth Mittal outlines the company’s strategy in the competitive GLP-1 market. Focusing on liraglutide’s launch in the US and Europe, he highlights opportunities in emerging markets. While semaglutide is a longer-term play, Biocon is actively filing for approvals, anticipating launches in 2027.
Dipan Mehta bets on NBFCs, says cleaned-up books signal fresh upside
Dipan Mehta of Elixir Equities offers a selective outlook, favoring NBFCs and pharma while cautioning on metals and avoiding certain largecaps. He sees strength in diversified NBFCs and potential in solar despite current underperformance, but advises patience in real estate and a clear avoid on tobacco stocks like ITC.
Positive Breakout: These 13 stocks cross above their 200 DMAs
In the Nifty500 pack, 13 stocks’ closing prices crossed above their 200 DMA (Daily Moving Averages) on February 25, 2026, according to stockedge.com’s technical scan data. The 200-day daily moving average (DMA) is used by traders as a key indicator for determining the overall trend in a particular stock. As long as the stock is […]
US Stock Market | Wall Street extends tech-powered rally as AI worries abate; Nvidia reports
Wall Street indexes climbed to two-week highs, led by tech stocks, as optimism about AI’s potential benefits overshadowed concerns about disruption and costs. Nvidia’s strong earnings fueled the rally, with the Nasdaq showing the largest percentage gain. Investors are weighing existential AI risks against potential returns.
SP Group’s Rs 25,000 crore bond issue price likely to be lower
Shapoorji Pallonji Group is set to raise approximately ₹25,000 crore through a bond issue. This fundraising effort, planned for early April, is expected to have a lower pricing than previous borrowings. Improved prospects for asset sales and a potential settlement regarding its stake in Tata Sons are boosting investor confidence.